Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Sirnaomics Starts Trial of Lead siRNA Therapy for Fat Reduction

publication date: Nov 9, 2022

Sirnaomics, a Suzhou-Maryland RNAi company, has dosed the first patient in a Phase I clinical study of its lead siRNA (small interfering RNA) candidate as a fat reduction agent in adults undergoing abdominoplasty. STP705 is already being tested as a therapy for cholangiocarcinoma, non-melanoma skin cancer and hypertrophic scar. Sirnaomics said the dose setting trial will examine STP705 for its fat reduction and subcutaneous tissue remodeling effects, pointing out that existing therapies require multiple sessions to produce only mild effects. More details....

Stock Symbol: (HK: 2257)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital